BVF as of March 31, 2024
Portfolio Holdings for BVF
BVF holds 62 positions in its portfolio as reported in the March 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Moonlake Immunotherapeutics Class A Ord (MLTX) | 30.0 | $1.1B | 22M | 50.23 | |
Kymera Therapeutics (KYMR) | 5.7 | $208M | 5.2M | 40.20 | |
Revolution Medicines (RVMD) | 5.3 | $193M | 6.0M | 32.23 | |
4d Molecular Therapeutics In (FDMT) | 3.4 | $125M | 3.9M | 31.86 | |
Gh Research Ordinary Shares (GHRS) | 3.0 | $111M | 10M | 10.66 | |
Janux Therapeutics (JANX) | 3.0 | $110M | 2.9M | 37.65 | |
Mirum Pharmaceuticals (MIRM) | 3.0 | $110M | 4.4M | 25.12 | |
Protagonist Therapeutics (PTGX) | 3.0 | $109M | 3.8M | 28.93 | |
Ionis Pharmaceuticals (IONS) | 2.9 | $105M | 2.4M | 43.35 | |
Olema Pharmaceuticals (OLMA) | 2.8 | $103M | 9.1M | 11.32 | |
Kura Oncology (KURA) | 2.8 | $102M | 4.8M | 21.33 | |
Xoma Corp Del Com New (XOMA) | 2.4 | $87M | 3.6M | 24.05 | |
Cg Oncology | 2.3 | $83M | 1.9M | 43.90 | |
Tyra Biosciences (TYRA) | 2.1 | $76M | 4.7M | 16.40 | |
Essa Pharma Com New (EPIX) | 2.0 | $74M | 8.7M | 8.49 | |
Zymeworks Del (ZYME) | 1.7 | $62M | 5.9M | 10.52 | |
Galapagos Nv Spon Adr (GLPG) | 1.6 | $60M | 1.9M | 32.20 | |
Cullinan Oncology (CGEM) | 1.5 | $55M | 3.2M | 17.04 | |
Merus N V (MRUS) | 1.5 | $53M | 1.2M | 45.03 | |
Ideaya Biosciences (IDYA) | 1.4 | $51M | 1.2M | 43.88 | |
Annexon (ANNX) | 1.4 | $50M | 7.0M | 7.17 | |
Repare Therapeutics Ord (RPTX) | 1.3 | $49M | 10M | 4.71 | |
89bio (ETNB) | 1.3 | $47M | 4.0M | 11.64 | |
Syndax Pharmaceuticals (SNDX) | 1.2 | $45M | 1.9M | 23.80 | |
Ac Immune Sa SHS (ACIU) | 1.2 | $43M | 15M | 2.96 | |
Third Harmonic Bio (THRD) | 1.1 | $41M | 4.4M | 9.44 | |
Engene Holdings (ENGN) | 1.0 | $38M | 2.3M | 16.95 | |
Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.0 | $36M | 1.5M | 23.65 | |
Structure Therapeutics Sponsored Ads (GPCR) | 1.0 | $35M | 813k | 42.86 | |
Roivant Sciences SHS (ROIV) | 0.8 | $29M | 2.7M | 10.54 | |
Glycomimetics (GLYC) | 0.8 | $29M | 9.5M | 3.00 | |
Tscan Therapeutics (TCRX) | 0.7 | $24M | 3.0M | 7.94 | |
Allakos (ALLK) | 0.6 | $21M | 17M | 1.26 | |
Verastem Com New (VSTM) | 0.5 | $20M | 1.7M | 11.80 | |
Calliditas Therapeutics Ab Sponsered Ads (CALT) | 0.4 | $16M | 750k | 21.65 | |
Cytomx Therapeutics (CTMX) | 0.4 | $14M | 6.6M | 2.18 | |
Elevation Oncology (ELEV) | 0.3 | $12M | 2.3M | 5.13 | |
Ovid Therapeutics (OVID) | 0.3 | $12M | 3.9M | 3.05 | |
Immunic (IMUX) | 0.3 | $12M | 8.9M | 1.32 | |
Vistagen Therapeutics Ord (VTGN) | 0.3 | $11M | 2.0M | 5.28 | |
Eledon Pharmaceuticals (ELDN) | 0.2 | $8.9M | 4.3M | 2.06 | |
Verve Therapeutics (VERV) | 0.2 | $8.6M | 650k | 13.28 | |
Ikena Oncology (IKNA) | 0.2 | $6.8M | 4.8M | 1.42 | |
Cidara Therapeutics Inc Common Stock Usd 0.0001 (CDTX) | 0.2 | $6.3M | 6.9M | 0.92 | |
Vigil Neuroscience (VIGL) | 0.2 | $6.2M | 1.8M | 3.41 | |
Delcath Sys Com New (DCTH) | 0.2 | $5.7M | 1.2M | 4.77 | |
Unicycive Therapeutics (UNCY) | 0.1 | $5.0M | 3.6M | 1.38 | |
Engene Holdings *w Exp 10/31/202 (ENGNW) | 0.1 | $4.9M | 945k | 5.20 | |
Sab Biotherapeutics Com New (SABS) | 0.1 | $4.2M | 918k | 4.54 | |
Lexicon Pharmaceuticals Com New (LXRX) | 0.1 | $4.0M | 1.7M | 2.40 | |
An2 Therapeutics (ANTX) | 0.1 | $4.0M | 1.2M | 3.25 | |
Kronos Bio (KRON) | 0.1 | $3.8M | 2.9M | 1.30 | |
Pieris Pharmaceuticals (PIRS) | 0.1 | $3.8M | 21M | 0.18 | |
Viracta Therapeutics (VIRX) | 0.1 | $3.7M | 3.6M | 1.02 | |
Inventiva Sa Ads (IVA) | 0.1 | $2.5M | 686k | 3.62 | |
Forte Biosciences (FBRX) | 0.1 | $2.1M | 3.0M | 0.70 | |
Molecular Partners Ads (MOLN) | 0.0 | $1.7M | 443k | 3.88 | |
Molecular Templates Com New (MTEM) | 0.0 | $1.2M | 522k | 2.24 | |
Nls Pharmaceutics SHS (NLSP) | 0.0 | $1.0M | 5.7M | 0.18 | |
Aslan Pharmaceuticals Spon Ads New (ASLN) | 0.0 | $646k | 1.0M | 0.62 | |
Corvus Pharmaceuticals (CRVS) | 0.0 | $643k | 361k | 1.78 | |
Rezolute Com New (RZLT) | 0.0 | $487k | 191k | 2.55 |